We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

16 hedge funds and large institutions have $3.87M invested in Gain Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.73% less ownership

Funds ownership: 9.78% → 9.05% (-0.73%)

19% less capital invested

Capital invested by funds: $4.75M → $3.87M (-$879K)

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$114K
2
BlackRock
BlackRock
New York
+$44.5K
3
CC
Cannell Capital
Wyoming
+$9.49K
4
UBS Group
UBS Group
Switzerland
+$7.97K
5
HI
Hoey Investments
Pennsylvania
+$1.73K

Top Sellers

Rank Fund Capital Flow
1
TI
Telemetry Investments
New York
-$276K
2
V
Veritable
Delaware
-$103K
3
Jane Street
Jane Street
New York
-$48K
4
Millennium Management
Millennium Management
New York
-$44K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$37.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$1.97M – – –
TI
2
Telemetry Investments
New York
$576K -$276K -80,000 -33%
CM
3
CM Management
Florida
$450K – – –
PCM
4
Prelude Capital Management
New York
$209K – – –
BCM
5
Bridgeway Capital Management
Texas
$144K – – –
Royal Bank of Canada
6
Royal Bank of Canada
Ontario, Canada
$140K -$37.9K -11,000 -22%
Renaissance Technologies
7
Renaissance Technologies
New York
$119K +$114K +33,100 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$92K +$655 +190 +0.7%
BlackRock
9
BlackRock
New York
$85K +$44.5K +12,904 +121%
Osaic Holdings
10
Osaic Holdings
Arizona
$36K +$172 +50 +0.5%
UBS Group
11
UBS Group
Switzerland
$23K +$7.97K +2,311 +56%
Wells Fargo
12
Wells Fargo
California
$10K +$7 +2 +0.1%
CC
13
Cannell Capital
Wyoming
$10K +$9.49K +2,751 New
Morgan Stanley
14
Morgan Stanley
New York
$3K -$10 -3 -0.4%
TRCT
15
Tower Research Capital (TRC)
New York
$3K +$424 +123 +21%
HI
16
Hoey Investments
Pennsylvania
$2K +$1.73K +500 New
V
17
Veritable
Delaware
– -$103K -25,064 Closed
Jane Street
18
Jane Street
New York
– -$48K -11,722 Closed
Millennium Management
19
Millennium Management
New York
– -$44K -10,808 Closed

GANX Hedge Fund Activity: Q2 2022 in Review

16 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2022, worth a combined $3.87M — down 19% from $4.75M a quarter earlier.

Fund positioning in GANX was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $114K. The largest seller was Telemetry Investments, cutting an estimated $276K.

  • 16 institutional investors held Gain Therapeutics (GANX) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $3.87M of Gain Therapeutics stock for Q2 2022, down 19% quarter-over-quarter.
  • 3 funds opened new Gain Therapeutics positions in Q2 2022 and 3 closed out, a net change of 0 holders.
  • The largest Gain Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $114K added.
  • The largest Gain Therapeutics seller in Q2 2022 was Telemetry Investments, an estimated $276K sold.

Based on aggregated 13F filings for Q2 2022.